Affymax files for approval of kidney disease drug - BusinessWeek PDF Print
BusinessWeek
It is intended to treat anemia in patients who have chronic kidney failure and are on dialysis. Affymax and Takeda previously called the drug candidate Hematide. Takeda, a Japanese drugmaker, has marketing rights outside the US Affymax, of Palo Alto, ...
Affymax Submits NDA For Peginesatide RTT News
Takeda/Affymax file anaemia drug in USA Pharma Times
Affymax and Takeda Announce the Submission of a New Drug Application for

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.